The prognosis and risk factors for patients with complex karyotype myelodysplastic syndrome undergoing allogeneic haematopoietic stem cell transplantation
- 19 October 2023
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 204 (2) , 612-622
Abstract
Summary: Allogeneic haematopoietic stem cell transplantation (HCT) is the curative treatment for myelodysplastic syndrome with a complex karyotype (CK‐MDS). However, only a few studies have been limited to patients with CK‐MDS undergoing allogeneic HCT. This study aimed to identify the risk factors for patients with CK‐MDS undergoing allogeneic HCT. We included 691 patients with CK‐MDS who received their first allogeneic HCT. The overall survival (OS) was the primary end‐point, estimated using the Kaplan–Meier method. Prognostic factors were identified using a Cox proportional hazards model. The 3‐year OS was 29.8% (95% confidence interval [CI]: 26.3–33.3). In the multivariable analysis, older age (hazard ratio [HR]: 1.44, 95% CI: 1.11–1.88), male sex (HR: 1.38, 95% CI: 1.11–1.71), poor haematopoietic cell transplant comorbidity index (HR: 1.47, 95% CI: 1.20–1.81), red blood cell transfusion requirement (HR: 1.58, 95% CI: 1.13–2.20), platelet transfusion requirement (HR: 1.85, 95% CI: 1.46–2.35), not‐complete remission (HR: 1.55, 95% CI: 1.16–2.06), a high number of karyotype abnormality (HR: 1.63, 95% CI: 1.18–2.25) and monosomal karyotype (HR: 1.49, 95% CI: 1.05–2.12) were significantly associated with OS. Thus, the 3‐year OS of allogeneic HCT was 29.8% in patients with CK‐MDS, and we identified risk factors associated with poor OS.Keywords
This publication has 38 references indexed in Scilit:
- Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS)Blood, 2013
- Comparison of imputation methods for missing laboratory data in medicineBMJ Open, 2013
- Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemiaLeukemia, 2012
- Revised International Prognostic Scoring System for Myelodysplastic SyndromesBlood, 2012
- MissForest—non-parametric missing value imputation for mixed-type dataBioinformatics, 2011
- Coalesced Multicentric Analysis of 2,351 Patients With Myelodysplastic Syndromes Indicates an Underestimation of Poor-Risk Cytogenetics of Myelodysplastic Syndromes in the International Prognostic Scoring SystemJournal of Clinical Oncology, 2011
- Defining the Intensity of Conditioning Regimens: Working DefinitionsTransplantation and Cellular Therapy, 2009
- Reduced-Intensity Conditioning Regimen Workshop: Defining the Dose Spectrum. Report of a Workshop Convened by the Center for International Blood and Marrow Transplant ResearchTransplantation and Cellular Therapy, 2009
- Monosomal Karyotype in Acute Myeloid Leukemia: A Better Indicator of Poor Prognosis Than a Complex KaryotypeJournal of Clinical Oncology, 2008
- Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCTBlood, 2005